Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Current Pharmacology Reports is Scopus-indexed (Q2, CiteScore 4.6), WoS ESCI. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Science and Business Media Deutschland GmbH.
Checked against the index lists dated .
ISSN 2198-641XVerify ISSN ↗
Publisher: Springer Science and Business Media Deutschland GmbH
Cost to publish: About US$4,790 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Genetics | 172 / 357 | 51st | Q2 |
| Pharmacology | 165 / 328 | 49th | Q3 |
| Drug Discovery | 85 / 161 | 47th | Q3 |
| Biochemistry | 241 / 448 | 46th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2015–present, best quartile Q2, CiteScore 4.6.
Current Pharmacology Reports is Q2 in Genetics (rank 172 of 357), Q3 in Pharmacology (rank 165 of 328) and Q3 in Drug Discovery (rank 85 of 161), by CiteScore 2025. It is ranked in 4 subject areas in all.
Current Pharmacology Reports is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.6, which places it in quartile Q2 at the 51st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.499, quartile Q3, with an H-index of 43.
The publisher lists an article processing charge of about US$4,790 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Current Pharmacology Reports is published by Springer Science and Business Media Deutschland GmbH. Its ISSN is 2198-641X.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Current Pharmacology Reports has an h-index of 48 and a 2-year mean of 2.97 citations per paper (OpenAlex). Its Scopus CiteScore is 4.6, quartile Q2. On 2-year citations it ranks #139 of 353 Scopus journals in Genetics.
Current Pharmacology Reports published 50 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2024–2026), authors are most often from India (51.7%), United States (18.9%) and Malaysia (3.6%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags 2 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.